Taiwan consensus of pharmacological treatment for bipolar disorder

Ya Mei Bai, Ching Jui Chang, Shang Ying Tsai, Yi Chyan Chen, Mei Chun Hsiao, Cheng Ta Li, Peichi Tu, Shang Wen Chang, Winston W. Shen, Tung Ping Su

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Bipolar disorder is an important psychiatric disorder with different disease phases. The pharmacological treatment is complicated, and is updated frequently as new research evidence emerges. For the purpose of international collaboration, research, and education, the Taiwan consensus of pharmacological treatment for bipolar disorders was initiated by the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) - the Bipolar Chapter, which was established in August 2010 and approved as a member of International Society of Bipolar Disorder. TSBPN is the country member of the World Federation of Societies of Biological Psychiatry (WFSBP). The development of the Taiwan consensus for bipolar disorder was mainly based on the template of WFSBP Guidelines, with references to other international guidelines including the Canadian Network for Mood and Anxiety Treatments, and British Association for Psychopharmacology. We have also added Taiwanese experts' experience, Taiwan national health insurance data, and the indications for the pharmacological treatment of bipolar disorder given by the Taiwan Department of Health, to emphasize the balance between efficacy and safety, and to make this consensus a concise, empirical, and important reference for clinical psychiatric practice.

Original languageEnglish
Pages (from-to)547-556
Number of pages10
JournalJournal of the Chinese Medical Association
Volume76
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Taiwan
Bipolar Disorder
Biological Psychiatry
Consensus
Pharmacology
Psychiatry
Guidelines
National Health Programs
Research
Anxiety
Safety
Education
Health

Keywords

  • Bipolar disorder
  • Consensus
  • Pharmacotherapy
  • Taiwan

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Taiwan consensus of pharmacological treatment for bipolar disorder. / Bai, Ya Mei; Chang, Ching Jui; Tsai, Shang Ying; Chen, Yi Chyan; Hsiao, Mei Chun; Li, Cheng Ta; Tu, Peichi; Chang, Shang Wen; Shen, Winston W.; Su, Tung Ping.

In: Journal of the Chinese Medical Association, Vol. 76, No. 10, 10.2013, p. 547-556.

Research output: Contribution to journalArticle

Bai, YM, Chang, CJ, Tsai, SY, Chen, YC, Hsiao, MC, Li, CT, Tu, P, Chang, SW, Shen, WW & Su, TP 2013, 'Taiwan consensus of pharmacological treatment for bipolar disorder', Journal of the Chinese Medical Association, vol. 76, no. 10, pp. 547-556. https://doi.org/10.1016/j.jcma.2013.06.013
Bai, Ya Mei ; Chang, Ching Jui ; Tsai, Shang Ying ; Chen, Yi Chyan ; Hsiao, Mei Chun ; Li, Cheng Ta ; Tu, Peichi ; Chang, Shang Wen ; Shen, Winston W. ; Su, Tung Ping. / Taiwan consensus of pharmacological treatment for bipolar disorder. In: Journal of the Chinese Medical Association. 2013 ; Vol. 76, No. 10. pp. 547-556.
@article{99a2cd5f36374088bb2d03b0dab93295,
title = "Taiwan consensus of pharmacological treatment for bipolar disorder",
abstract = "Bipolar disorder is an important psychiatric disorder with different disease phases. The pharmacological treatment is complicated, and is updated frequently as new research evidence emerges. For the purpose of international collaboration, research, and education, the Taiwan consensus of pharmacological treatment for bipolar disorders was initiated by the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) - the Bipolar Chapter, which was established in August 2010 and approved as a member of International Society of Bipolar Disorder. TSBPN is the country member of the World Federation of Societies of Biological Psychiatry (WFSBP). The development of the Taiwan consensus for bipolar disorder was mainly based on the template of WFSBP Guidelines, with references to other international guidelines including the Canadian Network for Mood and Anxiety Treatments, and British Association for Psychopharmacology. We have also added Taiwanese experts' experience, Taiwan national health insurance data, and the indications for the pharmacological treatment of bipolar disorder given by the Taiwan Department of Health, to emphasize the balance between efficacy and safety, and to make this consensus a concise, empirical, and important reference for clinical psychiatric practice.",
keywords = "Bipolar disorder, Consensus, Pharmacotherapy, Taiwan",
author = "Bai, {Ya Mei} and Chang, {Ching Jui} and Tsai, {Shang Ying} and Chen, {Yi Chyan} and Hsiao, {Mei Chun} and Li, {Cheng Ta} and Peichi Tu and Chang, {Shang Wen} and Shen, {Winston W.} and Su, {Tung Ping}",
year = "2013",
month = "10",
doi = "10.1016/j.jcma.2013.06.013",
language = "English",
volume = "76",
pages = "547--556",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "10",

}

TY - JOUR

T1 - Taiwan consensus of pharmacological treatment for bipolar disorder

AU - Bai, Ya Mei

AU - Chang, Ching Jui

AU - Tsai, Shang Ying

AU - Chen, Yi Chyan

AU - Hsiao, Mei Chun

AU - Li, Cheng Ta

AU - Tu, Peichi

AU - Chang, Shang Wen

AU - Shen, Winston W.

AU - Su, Tung Ping

PY - 2013/10

Y1 - 2013/10

N2 - Bipolar disorder is an important psychiatric disorder with different disease phases. The pharmacological treatment is complicated, and is updated frequently as new research evidence emerges. For the purpose of international collaboration, research, and education, the Taiwan consensus of pharmacological treatment for bipolar disorders was initiated by the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) - the Bipolar Chapter, which was established in August 2010 and approved as a member of International Society of Bipolar Disorder. TSBPN is the country member of the World Federation of Societies of Biological Psychiatry (WFSBP). The development of the Taiwan consensus for bipolar disorder was mainly based on the template of WFSBP Guidelines, with references to other international guidelines including the Canadian Network for Mood and Anxiety Treatments, and British Association for Psychopharmacology. We have also added Taiwanese experts' experience, Taiwan national health insurance data, and the indications for the pharmacological treatment of bipolar disorder given by the Taiwan Department of Health, to emphasize the balance between efficacy and safety, and to make this consensus a concise, empirical, and important reference for clinical psychiatric practice.

AB - Bipolar disorder is an important psychiatric disorder with different disease phases. The pharmacological treatment is complicated, and is updated frequently as new research evidence emerges. For the purpose of international collaboration, research, and education, the Taiwan consensus of pharmacological treatment for bipolar disorders was initiated by the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) - the Bipolar Chapter, which was established in August 2010 and approved as a member of International Society of Bipolar Disorder. TSBPN is the country member of the World Federation of Societies of Biological Psychiatry (WFSBP). The development of the Taiwan consensus for bipolar disorder was mainly based on the template of WFSBP Guidelines, with references to other international guidelines including the Canadian Network for Mood and Anxiety Treatments, and British Association for Psychopharmacology. We have also added Taiwanese experts' experience, Taiwan national health insurance data, and the indications for the pharmacological treatment of bipolar disorder given by the Taiwan Department of Health, to emphasize the balance between efficacy and safety, and to make this consensus a concise, empirical, and important reference for clinical psychiatric practice.

KW - Bipolar disorder

KW - Consensus

KW - Pharmacotherapy

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=84884587312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884587312&partnerID=8YFLogxK

U2 - 10.1016/j.jcma.2013.06.013

DO - 10.1016/j.jcma.2013.06.013

M3 - Article

C2 - 23933343

AN - SCOPUS:84884587312

VL - 76

SP - 547

EP - 556

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 10

ER -